Scilex Holding (SCLX) Registration filing summary

Company overview and business model

• Focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities.

• Commercial products include ZTlido (lidocaine topical system), ELYXYB (celecoxib oral solution), and GLOPERBA (liquid colchicine), with three late-stage product candidates in development.

• Employs a dedicated sales force and leverages direct distribution networks to national and regional wholesalers and pharmacies.

• Holds exclusive global rights (excluding Japan) to proprietary lidocaine patch technology and licenses for other products.

• Pursues a patient-first approach, emphasizing safer, more effective non-opioid therapies.

Financial performance and metrics

• Net revenue for 2024 was $56.6 million, up from $46.7 million in 2023, driven by increased sales of ZTlido and ELYXYB and the launch of GLOPERBA.

• Net loss for 2024 was $72.8 million, an improvement from a net loss of $114.3 million in 2023.

• As of March 31, 2025, cash and cash equivalents were $5.8 million, with an accumulated deficit of $589.1 million.

• Cost of revenue for 2024 was $16.7 million, with research and development expenses of $9.6 million and selling, general, and administrative expenses of $119.0 million.

• Auditor's report includes a going concern warning due to recurring losses, negative working capital, and substantial cumulative net losses.

Use of proceeds and capital allocation

• May receive up to $100 million in gross proceeds from the Tumim Purchase Agreement, with actual proceeds dependent on share sales.

• Net proceeds are intended for working capital and general corporate purposes, including R&D, regulatory, clinical trials, acquisitions, business combinations, and debt repayment.

• Management retains broad discretion over the use of proceeds.